IL301707A - Imidazopiperazine inhibitors of transcription-activating proteins - Google Patents
Imidazopiperazine inhibitors of transcription-activating proteinsInfo
- Publication number
- IL301707A IL301707A IL301707A IL30170723A IL301707A IL 301707 A IL301707 A IL 301707A IL 301707 A IL301707 A IL 301707A IL 30170723 A IL30170723 A IL 30170723A IL 301707 A IL301707 A IL 301707A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- recited
- disease
- compound
- chosen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086728P | 2020-10-02 | 2020-10-02 | |
| PCT/US2021/052898 WO2022072648A1 (en) | 2020-10-02 | 2021-09-30 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301707A true IL301707A (en) | 2023-05-01 |
Family
ID=80950902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301707A IL301707A (en) | 2020-10-02 | 2021-09-30 | Imidazopiperazine inhibitors of transcription-activating proteins |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559497B2 (enExample) |
| EP (1) | EP4221709B1 (enExample) |
| JP (1) | JP2023544173A (enExample) |
| KR (1) | KR20230080441A (enExample) |
| CN (1) | CN116261454A (enExample) |
| AU (1) | AU2021355480B2 (enExample) |
| CA (1) | CA3193745A1 (enExample) |
| DK (1) | DK4221709T3 (enExample) |
| IL (1) | IL301707A (enExample) |
| MX (1) | MX2023003785A (enExample) |
| WO (1) | WO2022072648A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| CA3193745A1 (en) | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
| AU2024331409A1 (en) * | 2023-08-30 | 2026-03-12 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as cbp/p300 degraders and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008078291A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| CN101686989B (zh) * | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN102076694A (zh) | 2008-06-25 | 2011-05-25 | 埃科特莱茵药品有限公司 | 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物 |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| US9695176B2 (en) | 2012-10-18 | 2017-07-04 | Bristol-Myers Squibb Company | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists |
| US9371282B2 (en) * | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| MX382033B (es) * | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| JP6820254B2 (ja) | 2014-10-10 | 2021-01-27 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| EP3632915A1 (en) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3445750A4 (en) | 2016-04-18 | 2019-11-27 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| JP7014736B2 (ja) | 2016-05-24 | 2022-02-01 | ジェネンテック， インコーポレイテッド | がんの処置のためのピラゾロピリジン誘導体 |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| RU2020131507A (ru) | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| CA3193745A1 (en) | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
-
2021
- 2021-09-30 CA CA3193745A patent/CA3193745A1/en active Pending
- 2021-09-30 MX MX2023003785A patent/MX2023003785A/es unknown
- 2021-09-30 IL IL301707A patent/IL301707A/en unknown
- 2021-09-30 WO PCT/US2021/052898 patent/WO2022072648A1/en not_active Ceased
- 2021-09-30 DK DK21876484.3T patent/DK4221709T3/da active
- 2021-09-30 KR KR1020237014382A patent/KR20230080441A/ko active Pending
- 2021-09-30 AU AU2021355480A patent/AU2021355480B2/en active Active
- 2021-09-30 CN CN202180068106.3A patent/CN116261454A/zh active Pending
- 2021-09-30 JP JP2023520080A patent/JP2023544173A/ja active Pending
- 2021-09-30 EP EP21876484.3A patent/EP4221709B1/en active Active
-
2023
- 2023-03-13 US US18/182,620 patent/US12559497B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023544173A (ja) | 2023-10-20 |
| AU2021355480A1 (en) | 2023-05-04 |
| EP4221709B1 (en) | 2026-01-21 |
| WO2022072648A1 (en) | 2022-04-07 |
| AU2021355480B2 (en) | 2026-03-05 |
| CA3193745A1 (en) | 2022-04-07 |
| CN116261454A (zh) | 2023-06-13 |
| US20230312588A1 (en) | 2023-10-05 |
| EP4221709A4 (en) | 2024-10-02 |
| KR20230080441A (ko) | 2023-06-07 |
| EP4221709A1 (en) | 2023-08-09 |
| MX2023003785A (es) | 2023-04-26 |
| US12559497B2 (en) | 2026-02-24 |
| DK4221709T3 (da) | 2026-04-07 |
| AU2021355480A9 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12186324B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| US12559497B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| EP3316887B1 (en) | Gls1 inhibitors for treating disease | |
| WO2019195846A1 (en) | Imidazopiperazinone inhibitors of transcription activating proteins | |
| AU2020391425A1 (en) | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease | |
| WO2016004413A2 (en) | Gls1 inhibitors for treating disease | |
| US12540139B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| BR112017028309B1 (pt) | Composto e composição | |
| HK1253238B (en) | Gls1 inhibitors for treating disease |